4/16
06:00 am
algs
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
High
Report
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
4/14
04:05 pm
algs
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
High
Report
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
3/27
07:25 am
algs
Aligos Therapeutics (ALGS) was upgraded by Jefferies Financial Group Inc. to "strong-buy".
Medium
Report
Aligos Therapeutics (ALGS) was upgraded by Jefferies Financial Group Inc. to "strong-buy".
3/26
10:21 am
algs
Aligos Therapeutics (ALGS) is now covered by Westpark Capital. They set a "buy" rating and a $48.00 price target on the stock.
Low
Report
Aligos Therapeutics (ALGS) is now covered by Westpark Capital. They set a "buy" rating and a $48.00 price target on the stock.
3/20
08:07 am
algs
Aligos Therapeutics (ALGS) was upgraded by Jefferies Financial Group Inc. to "strong-buy".
Medium
Report
Aligos Therapeutics (ALGS) was upgraded by Jefferies Financial Group Inc. to "strong-buy".
3/19
09:02 am
algs
Aligos Therapeutics (ALGS) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $48.00 price target on the stock.
Medium
Report
Aligos Therapeutics (ALGS) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $48.00 price target on the stock.
3/11
01:40 pm
algs
Aligos Therapeutics (ALGS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
Medium
Report
Aligos Therapeutics (ALGS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
3/7
02:59 am
algs
Medium
Report
3/5
08:34 am
algs
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Medium
Report
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
3/5
08:00 am
algs
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
High
Report
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
2/26
08:00 am
algs
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
Medium
Report
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
2/23
08:00 am
algs
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
Low
Report
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
1/30
08:00 am
algs
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/21
10:32 am
algs
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates [Yahoo! Finance]
Medium
Report
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates [Yahoo! Finance]
1/21
08:00 am
algs
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
Low
Report
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates